NASDAQ:PRFX

PainReform (PRFX) Stock Price, News & Analysis

PainReform logo
$0.48 -0.15 (-23.68%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.53 +0.05 (+11.39%)
As of 11/20/2026 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About PainReform Stock (NASDAQ:PRFX)

Advanced

Key Stats

Today's Range
$0.46
▼
$0.60
50-Day Range
$0.48
▼
$1.02
52-Week Range
$0.46
▼
$7.95
Volume
69,820 shs
Average Volume
276,903 shs
Market Capitalization
$1.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

PainReform Ltd. is an Israel-based specialty pharmaceutical company developing treatments for postoperative pain. Its lead candidate, PRF-110, is an extended-release formulation of the local anesthetic ropivacaine designed for administration at a surgical site to provide pain relief after surgery.

The company’s development work has focused on evaluating PRF-110 for postoperative pain management in procedures including bunion surgery and hernia repair. PainReform’s research centers on drug-delivery approaches intended to extend the effect of local anesthetics.

AI Generated. May Contain Errors.

PainReform Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

PRFX MarketRank™: 
0.87505258729 of 5 stars

PainReform scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PainReform has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    PainReform has only been the subject of 1 research reports in the past 90 days.

  • Read more about PainReform's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PainReform is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PainReform is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PainReform has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.25% of the float of PainReform has been sold short.
  • Short Interest Ratio / Days to Cover

    PainReform has a short interest ratio ("days to cover") of 0.39, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PainReform has recently decreased by 35.90%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    PainReform does not currently pay a dividend.

  • Dividend Growth

    PainReform does not have a long track record of dividend growth.

    • Insider Buying vs. Insider Selling

      In the past three months, PainReform insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      34.40% of the stock of PainReform is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      37.28% of the stock of PainReform is held by institutions.

    • Read more about PainReform's insider trading history.
    Receive PRFX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter.

    SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    PRFX Stock News Headlines

    $0. Later: $29.97.
    Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
    See More Headlines

    PRFX Stock Analysis - Frequently Asked Questions

    PainReform's stock was trading at $3.2090 on January 1st, 2026. Since then, PRFX shares have decreased by 85.2% and is now trading at $0.4758.

    PainReform Ltd. (NASDAQ:PRFX) issued its quarterly earnings results on Thursday, September, 3rd. The company reported ($1.13) earnings per share for the quarter. The firm had revenue of $7 thousand for the quarter.

    PainReform shares reverse split on the morning of Thursday, November 21st 2024.The 1-4 reverse split was announced on Monday, November 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

    PainReform (PRFX) raised $23 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,550,000 shares at a price of $8.00-$10.00 per share. Maxim Group and Joseph Gunnar acted as the underwriters for the IPO.

    Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that PainReform investors own include Workhorse Group (WKHS), AMC Entertainment (AMC), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Tesla (TSLA), Boeing (BA) and Novavax (NVAX).

    Company Calendar

    Last Earnings
    9/03/2026
    Today
    11/22/2026
    Fiscal Year End
    12/31/2026

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Industry
    Pharmaceuticals
    Sub-Industry
    Pharmaceuticals
    Current Symbol
    NASDAQ:PRFX
    CIK
    1801834
    Fax
    N/A
    Employees
    7
    Year Founded
    N/A

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    N/A
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    N/A
    Return on Assets
    N/A

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    5.07
    Quick Ratio
    N/A

    Sales & Book Value

    Annual Sales
    $31 thousand
    Price / Sales
    46.69
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $23.07 per share
    Price / Book
    0.02

    Miscellaneous

    Outstanding Shares
    3,042,000
    Free Float
    1,996,000
    Market Cap
    $1.45 million
    Optionable
    Not Optionable
    Beta
    1.16
     The Best Nuclear Energy Stocks to Buy Cover

    Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

    Get This Free Report

    This page (NASDAQ:PRFX) was last updated on 11/20/2026 by MarketBeat.com Staff.
    From Our Partners